OncoMatch/Clinical Trials/NCT07190248
A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
Is NCT07190248 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Calderasib · Pembrolizumab (+) Berahyaluronidase alfa · Pemetrexed · Cisplatin · Carboplatin — Researchers want to learn if the study medicines calderasib and subcutaneous (SC) pembrolizumab can be used to treat non-small cell lung cancer (NSCLC) when given together. Calderasib is a targeted therapy for the KRAS G12C mutation. The goal of this study is to learn if people who receive calderasib with SC pembrolizumab live longer without the cancer growing or spreading than in people who receive SC pembrolizumab with chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Disease stage
Required: Stage IIIB, IIIC, IV: M1A, IV: M1B, IV: M1C
Prior therapy
Cannot have received: systemic anticancer therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Central Alabama Research ( Site 0108) · Birmingham, Alabama
- Stamford Hospital ( Site 0126) · Stamford, Connecticut
- Mount Sinai Cancer Center ( Site 0137) · Miami Beach, Florida
- New England Cancer Specialists ( Site 0139) · Westbrook, Maine
- New York Oncology Hematology, P.C. ( Site 0119) · Albany, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify